Published on September 24, 2009 at 8:01 AM
The Swedish biotech company Karo Bio (Reuters: KARO.ST) (STO:KARO) today announced that results from a clinical phase II study of the company’s thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.
The presentation will be made by Professor Paul W Ladenson from the Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, at the 80th Annual Meeting of the American Thyroid Association (ATA), held September 23-27, 2009, at the Breakers Hotel, Palm Beach, Florida, US.
The presentation will take place on September 26, at 3:30 pm US Eastern Time (EST) / 9:30 pm Central European Time (CET).
http://www.karobio.com/